| 6.94 -0.11 (-1.56%) | 03-10 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.73  |
1-year : | 12.48 |
| Resists | First : | 9.19 |
Second : | 10.68 |
| Pivot price | 9.43 |
|||
| Supports | First : | 6.77 |
Second : | 5.63 |
| MAs | MA(5) : | 8.22 |
MA(20) : | 9.52 |
| MA(100) : | 8.7 |
MA(250) : | 6.17  |
|
| MACD | MACD : | -0.5 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 6.3 |
D(3) : | 8.7 |
| RSI | RSI(14): 26.9 |
|||
| 52-week | High : | 12.25 | Low : | 2.65 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ENGN ] has closed below the lower bollinger band by 7.6%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 64.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 7.43 - 7.48 | 7.48 - 7.52 |
| Low: | 6.65 - 6.71 | 6.71 - 6.76 |
| Close: | 6.85 - 6.94 | 6.94 - 7.01 |
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Tue, 10 Mar 2026
ENGN: Detalimogene's pivotal data and unique profile position it to transform NMIBC treatment - TradingView
Tue, 10 Mar 2026
ENGN: Detalimogene offers a unique, highly tolerable NMIBC therapy with pivotal data updates in 2024 - TradingView
Tue, 10 Mar 2026
Engene stock price target lowered to $27 by Guggenheim on estimates - Investing.com
Tue, 10 Mar 2026
Raymond James Maintains Strong Buy on ENGN enGene Holdings Inc March 2026 - Meyka
Mon, 09 Mar 2026
enGene (NASDAQ:ENGN) Shares Gap Down - Here's Why - MarketBeat
Mon, 09 Mar 2026
HC Wainwright Reiterates 'Buy' Rating for enGene Holdings (ENGN) - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 67 (M) |
| Shares Float | 26 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 97.9 (%) |
| Shares Short | 1,500 (K) |
| Shares Short P.Month | 1,440 (K) |
| EPS | -2.29 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.22 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -28.9 % |
| Return on Equity (ttm) | -53.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.84 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -99 (M) |
| Levered Free Cash Flow | -60 (M) |
| PE Ratio | -3.04 |
| PEG Ratio | 0 |
| Price to Book value | 2.15 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.69 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|